Evaluation of the biological potential of ruthenium(II) complexes with cinnamic acid

Autor(es)

Graminha, Angelica E. ^{[1, 2]} ; Honorato, Joao ^[1] ; Dulcey, Liany Luna ^[2] ; Godoy, Luani Rezende ^[2] ; Barbosa, Marilia F. ^[3] ; Cominetti, Marcia R. ^[2] ; Menezes, Antonio C. ^[4] ; Batista, Alzir A. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Fed Sao Carlos, Dept Quim, BR-13565905 Sao Carlos, SP - Brazil

^[2] Univ Fed Sao Carlos, Dept Gerontol, BR-13565905 Sao Carlos, SP - Brazil

^[3] Univ Fed Alfenas, Inst Quim, BR-37130000 Alfenas, MG - Brazil

^[4] Univ Estadual Goias, Ctr Ciencias Exatas & Tecnol, BR-75132903 Anapolis, Go - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Journal of Inorganic Biochemistry; v. 206, MAY 2020.
• Citações Web of Science: 6

Resumo

In this work, we present the synthesis and characterization of five new ruthenium compounds with general formula {[}Ru(L)(dppb)(bipy)]PF6, where L = cinnamic acid derivatives, dppb = 1,4-bis(diphenylphosphino) butane and bipy = 2, 2'-bipyridine. The cytotoxicity of the complexes was evaluated against human breast tumor cells from the lines MCF-7, MDA-MB-231 and in human (MCF-10A) or mouse (L929) non-tumor cells. Complexes Ru(L-4)(dppb)(bipy)]PF6 (4) (L-4 = 4-hydroxycinnamic acid) and {[}Ru(L-5)(dppb)(bipy)]PF6 (5) (L-5 = 3,4-dihydroxycinnamic acid) were the most selective, presenting the highest values of selectivity indexes besides inhibited some processes related to tumor progression in vitro, such as invasion, migration, and adhesion in the MDA-MB-231 cell line. In addition, the complexes 4 and 5 were able to interact with Bovine Serum Albumin (BSA) and complex 5 showed antioxidant activity. (AU)

• Processo FAPESP: 14/19632-0 - Novos complexos de rutênio com ligantes bioativos: investigação do mecanismo de ação
• Beneficiário: Angelica Ellen Graminha
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 15/24940-8 - Avaliação da eficácia de mudanças estruturais do [10]-gingerol em combinação com o quimioterápico doxorubicina para o tratamento de câncer de mama: estudos in vitro e in vivo
• Beneficiário: Márcia Regina Cominetti
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 16/16312-0 - Citotoxidade e mecanismo de ação de complexos de rutênio contendo produtos naturais ou derivados
• Beneficiário: Alzir Azevedo Batista
• Modalidade de apoio: Auxílio à Pesquisa - Regular